Submitted for Publication: March 8, 2014; final revision received July 16, 2014; accepted July 21, 2014.
Published Online: November 5, 2014. doi:10.1001/jamapsychiatry.2014.1734.
Study concept and design: Sarpal, Robinson, Lencz, Karlsgodt, Kane, Szeszko, Malhotra.
Acquisition, analysis, or interpretation of data: Sarpal, Robinson, Lencz, Argyelan, Ikuta, Karlsgodt, Gallego, Szeszko, Malhotra.
Drafting of the manuscript: Sarpal, Robinson, Lencz, Malhotra.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Sarpal, Lencz, Argyelan, Ikuta, Karlsgodt.
Obtained funding: Robinson, Kane, Malhotra.
Administrative, technical, or material support: Robinson, Kane, Malhotra.
Study supervision: Lencz, Szeszko, Malhotra.
Conflict of Interest Disclosures: Dr Robinson has been a consultant to Asubio and Shire and has received grants from Bristol-Myers Squibb, Janssen, and Otsuka. Dr Lencz is a consultant to Eli Lilly. Dr Kane is a shareholder in Medvante, Inc; has been a consultant for Amgen, Alkermes, Bristol-Myers Squibb, Eli Lilly, Forrest Pharmaceuticals, Genentech, H. Lundbeck Intracellular Therapeutics, Janssen Pharmaceutica, Jazz Pharmaceuticals, Johnson and Johnson, Lundbeck, Merck, Novartis, Otsuka, Pierre Fabre, Proteus, Reviva, Roche and Sunovion; and has been on the speaker’s bureau for Bristol-Myers Squibb, Eli Lilly, Janssen, and Otsuka. Dr Malhotra is a consultant to Genomind Inc. No other disclosures were reported.
Funding/Support: This study was supported by grants P50MH080173 to Dr Malhotra, P30MH090590 to Dr Kane, R01MH060004 to Dr Robinson, and R01MH076995 to Dr Szeszko from the National Institute of Mental Health.
Role of the Funder/Sponsor: The National Institute of Mental Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.